| Identification | Back Directory | [Name]
Ellipticine (hydrochloride) | [CAS]
5081-48-1 | [Synonyms]
NSC 71795 (hydrochloride)
Ellipticine hydrochloride(NSC 71795 hydrochloride) | [Molecular Formula]
C17H15ClN2 | [MOL File]
5081-48-1.mol | [Molecular Weight]
282.77 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO:4.4(Max Conc. mg/mL);15.56(Max Conc. mM) | [form ]
A crystalline solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Ellipticine (NSC 71795) hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities. | [in vivo]
Ellipticine (NSC 71795) treatment results in ellipticine-derived DNA adduct generation in several healthy organs (liver, kidney, lung, spleen, breast, heart and brain) and in DNA of mammary adenocarcinoma. The levels of Ellipticine (NSC 71795)-derived DNA adducts generated in these adenocarcinomas are almost 2-fold higher than in normal healthy mammary tissue. The induced expression of cytochrome b5 protein in liver of rats treated with Ellipticine (NSC 71795) suggests that cytochrome b5 may modulate the CYP-mediated bioactivation and detoxification of Ellipticine (NSC 71795)[3]. | [IC 50]
Topoisomerase II | [References]
[1] Stiborova M, et al. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23. DOI:10.5507/bp.2006.002
[2] Stiborova M, et al. Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol. 2011 Jun;4(2):98-105. DOI:10.2478/v10102-011-0017-7
[3] Stiborova M, et al. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN?) mice and pure enzymes. Int J Mol Sci. 2014 Dec 25;16(1):284-306. DOI:10.3390/ijms16010284 |
|
|